Authors

Jennifer Brown, MD, PhD, Harvard Medical School

Latest:

Dr. Carlisle on Chemoimmunotherapy as Frontline Standard in Squamous NSCLC

Jennifer Carlisle, MD, assistant professor, Winship Cancer Institute of Emory University, discusses how the use of chemoimmunotherapy has become the standard of care in the frontline treatment of patients with squamous non–small cell lung cancer.

Jennifer Chan, MD, MPH

Jennifer Chan, MD is the Clinical Director of the Gastrointestinal Cancer Center and the Director Carcinoid and Neuroendocrine Tumors Institute, as well as an Associate Professor of Medicine at Harvard Medical School.

Latest:

Dr Chan on Unmet Needs Addressed by the FDA Approval of Cabozantinib for pNET and epNET

Jennifer Chan, MD, MPH, discusses the prevalence of neuroendocrine tumors during Adolescent and Young Adult Cancer Awareness Week.

Jennifer E. Amengual, MD

Jennifer E. Amengual, MD, is the Herbert Irving Assistant Professor of Medicine in the Division of Hematology and Oncology at Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center.

Latest:

Dr Amengual on the Efficacy of Tazemetostat Plus Lenalidomide/Rituximab in Follicular Lymphoma

Jennifer Amengual, MD, discusses the efficacy of tazemetostat plus lenalidomide and rituximab in relapsed/refractory follicular lymphoma.

Jennifer Eads, MD

Latest:

Dr Eads on the Rationale for ECOG-ACRIN EA2174 in Esophageal/GEJ Adenocarcinoma

Jennifer R. Eads, MD, discusses the evaluation of the addition of nivolumab to neoadjuvant chemotherapy and radiation in esophageal/GEJ adenocarcinoma.

Jennifer Eads, MD, Case Western Reserve University

Jennifer K. Litton, MD

Latest:

Dr Litton on Navigating the Sequencing of PARP Inhibitors in Early-Stage TNBC

Jennifer K. Litton, MD, discusses challenges determining the optimal sequencing of PARP inhibitors in early-stage triple-negative breast cancer.

Jennifer Kelly, MD, PhD

Latest:

Lessons From the Other Side of the Bed: Physician Perspectives as a Cancer Patient

Oncologist Jennifer Kelly, MD, PhD, shares her personal experiences as a stomach cancer patient, recognizes the barriers between cancer care providers and patients, and suggests ways of improving these interactions.

Jennifer Kelly Shepphird, PhD

Latest:

Novel CAR T-Cell Therapies to Come From Amgen/Kite Pharma Collaboration

Amgen and Kite Pharma have announced that they will collaborate on the development of novel CAR T-cell immunotherapies, with Amgen providing cancer targets and Kite offering its engineered autologous cell therapy platform.

Jennifer Klem, PhD

Latest:

Deciding When Post-Mastectomy Radiation Therapy Is Warranted

For appropriate patients, postmastectomy radiation therapy is associated with improved locoregional control and better survival.

Jennifer L. Logan, MD, MPH

Latest:

Strategies for Lung Cancer Screening Implementation: Program Structure and Panel Profiles

The structure of lung cancer screening programs in the United States vary by resource availability, provider expertise, type of institution, and interests of the organization. Often these programs are developed through the reorganization of preexisting multidisciplinary models that have been providing services related to lung cancer.

Jennifer L. Malin, MD, PhD

Latest:

Cost-Effectiveness of 70-Gene MammaPrint Signature in Node-Negative Breast Cancer

Breast cancers with similar clinicopathologic characteristics may have strikingly different outcomes.

Jennifer L. Redmond, DrPH

Latest:

Tackling Patient Recruitment Challenges in Clinical Trials

Patients fear being a "guinea pig" or receiving a placebo, healthcare providers do not have time to keep up with all of the clinical trial information or talk with patients in depth, conducting clinical trials is very expensive for healthcare systems, and funding continues to decline for research.

Jennifer Ligibel, MD

Latest:

Dr. Ligibel Discusses Lifestyle Intervention in Breast Cancer

Jennifer Ligibel, MD, senior physician, Susan F. Smith Center for Women’s Cancer at Dana-Farber Cancer Institute, associate professor of medicine, Harvard Medical School, discusses lifestyle intervention in the treatment of patients with breast cancer.

Jennifer Litton, MD

Latest:

Dr. Litton on Responses to Talazoparib in BRCA1/2+ Early TNBC

Jennifer Litton, MD, highlights responses to talazoparib seen in patients with BRCA1/2-positive, early triple-negative breast cancer.

Jennifer Logan, MD, MPH

Latest:

Opening the Door for Novel Therapies in Triple-Negative Breast Cancer

During a recent OncLive Peer Exchange®, the expert panel focused on the development of immunotherapy and other notable successes based on recent presentations at the 2019 San Antonio Breast Cancer Symposium.

Jennifer L.W. Fink

Latest:

Microbiome Emerges as a Hot Topic in Cancer Research

Researchers have found relationships between the oral microbiome and esophageal cancer; between the vaginal and uterine microbiomes and endometrial cancer; and between the gut microbiome and the efficacy of checkpoint inhibitors.

Jennifer M. Kapo, MD

Latest:

Dr. Kapo on Addressing Palliative Care With Patients

Jennifer M. Kapo, MD, chief, palliative medicine, Yale Cancer Center, associate professor of medicine (medical oncology and geriatrics), Yale School of Medicine, discusses how oncologists can address palliative care with their patients.

Jennifer McQuade, MD, MS, MA, LAc

Latest:

Dr. McQuade on Age as a Predictor of Response to Neoadjuvant Immunotherapy in Melanoma

Jennifer McQuade, MD, MS, MA, LAc, discusses how age may serve as a predictor of response to neoadjuvant immunotherapy for patients with melanoma.

Jennifer Montes, MD

Latest:

Dr. Montes on the Relationship of MRI Imaging Characteristics With Race

Jennifer Montes, MD, NYU Langone Medical Center, discusses a recent study that examined the relationship of magnetic resonance imaging (MRI) characteristics with race in breast cancer.